

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Target number of patients agreed?	Min. number of patients agreed	Max. number of patients agreed	Target date to recruit patients agreed?	Date agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for closure of trial	Comments
12/WS/0300	114081	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.	Number Agreed	17	17	Date Agreed	31/03/2016	14	14	19/11/2015	Recruitment Finished	14 patients recruited. Sponsor closed recruitment 5 months early as global patient numbers met.
13/NW/0463	124757	Risk of Squamous Cell Carcinoma on Skin Areas Treated with Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%.	Number Agreed	10	10	Date Agreed	31/03/2016	6	6	21/12/2015	Withdrawn By Host	Recruitment stopped early at site at request of PI - Lack of patients meeting eligibility criteria.
14/SC/0033	146569	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	Number Agreed	5	5	Not Available / Not Agreed		3	3	26/01/2016	Recruitment Finished	Competitive recruitment across all sites. Global study participant target reached early.
15/SC/0397	183591	An evaluation of the tolerance, and acceptability of an amino acid based feed for children	Range Agreed	3	5	Date Agreed	15/07/2016	1	1	25/03/2016	Recruitment Finished	Competitive recruitment across sites.
15/LO/1035	164893	Multinational Abluminal Sirolimus Coated BiO-Engineered StentThe MASCOT Post Marketing Registry	Number Agreed	50	50	Not Available / Not Agreed		12	12	14/03/2016	Recruitment Finished	Competitive recruitment across sites.

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Target number of patients agreed?	Min. number of patients agreed	Max. number of patients agreed	Target date to recruit patients agreed?	Date agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for closure of trial	Comments
14/SC/0032	142458	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS	Number Agreed	5	5	Not Available / Not Agreed		4	4	21/07/2016	Recruitment Finished	Competitive recruitment across sites.